Posts Tagged ‘late-breaking clinical trials’

RSS

March 24th, 2014

ACC.14 Preview: Renal Denervation, TAVR Comparisons, and More

The ACC begins this Saturday in Washington, DC. Here’s a preview of some of the most highly anticipated late-breaking clinical trials: On Saturday morning at the opening session the world will finally learn more about the failure of Symplicity HTN-3, the Medtronic trial of renal denervation. Until recently, renal denervation was thought to be an extremely […]


January 31st, 2014

American College of Cardiology Announces Late-Breaking Clinical Trials

The American College of Cardiology announced the lineup of late-breaking clinical trials for its upcoming annual meeting in Washington, DC. The opening session will include the most eagerly anticipated trials — the main results of Symplicity HTN-3 and the  comparison of Corevalve and surgery in high-risk patients. Subsequent sessions will include several phase-3 trials of  PCSK9 inhibitors. Here […]


August 28th, 2013

American Heart Association Announces Late-Breaking Clinical Trials

There are still a few days left in August, and the European Society of Cardiology meeting doesn’t start until this weekend in Amsterdam. Nevertheless, the American Heart Association has released the list of late-breaking clinical trials for its annual meeting in November. Late-Breaking Clinical Trials 1: Acute Cardiovascular and Cerebrovascular Care Sunday, Nov 17, 2013, 4:00 PM – 5:19 PM […]


January 22nd, 2013

Trials of Niacin and AF Device Will Headline American College of Cardiology Program

Two big trials will highlight this year’s American College of Cardiology (ACC) meeting in March in San Francisco. First is the PREVAIL trial testing Boston Scientific’s long-anticipated Watchman left atrial appendage closure device for stroke prevention in patients with atrial fibrillation (AF). Second is the detailed presentation of the controversial failed HPS2-THRIVE trial of extended-release niacin and laropiprant. The […]